These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33128053)

  • 1. Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem.
    Ulitzka M; Carrara S; Grzeschik J; Kornmann H; Hock B; Kolmar H
    Protein Eng Des Sel; 2020 Sep; 33():. PubMed ID: 33128053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circumventing immunogenicity in the development of therapeutic antibodies.
    Holgate RG; Baker MP
    IDrugs; 2009 Apr; 12(4):233-7. PubMed ID: 19350467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies.
    Mattei AE; Gutierrez AH; Seshadri S; Tivin J; Ardito M; Rosenberg AS; Martin WD; De Groot AS
    MAbs; 2024; 16(1):2333729. PubMed ID: 38536724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.
    Harding FA; Stickler MM; Razo J; DuBridge RB
    MAbs; 2010; 2(3):256-65. PubMed ID: 20400861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires.
    Petersen BM; Ulmer SA; Rhodes ER; Gutierrez-Gonzalez MF; Dekosky BJ; Sprenger KG; Whitehead TA
    Front Immunol; 2021; 12():728694. PubMed ID: 34646268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
    Karle A; Spindeldreher S; Kolbinger F
    MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.
    De Groot AS; Terry F; Cousens L; Martin W
    Expert Rev Clin Pharmacol; 2013 Nov; 6(6):651-62. PubMed ID: 24164613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationally engineered proteins or antibodies with absent or reduced immunogenicity.
    Tangri S; LiCalsi C; Sidney J; Sette A
    Curr Med Chem; 2002 Dec; 9(24):2191-9. PubMed ID: 12470241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Monoclonal Antibodies: The Benefits of Humanization.
    Waldmann H
    Methods Mol Biol; 2019; 1904():1-10. PubMed ID: 30539464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we prevent immunogenicity of human protein drugs?
    Scott DW; De Groot AS
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i72-76. PubMed ID: 19995750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies.
    Harris CT; Cohen S
    BioDrugs; 2024 Mar; 38(2):205-226. PubMed ID: 38261155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunogenicity of therapeutic antibodies].
    Stas P; Lasters I
    Med Sci (Paris); 2009 Dec; 25(12):1070-7. PubMed ID: 20035681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of engineered antibodies.
    Hwang WY; Foote J
    Methods; 2005 May; 36(1):3-10. PubMed ID: 15848070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Deimmunization of Interferon Beta-1b by Identifying and Silencing Human T Cells Epitopes.
    Moradi Hasan-Abad A; Adabi E; Sadroddiny E; Khorramizadeh MR; Mazlomi MA; Mehravar S; Kardar GA
    Iran J Allergy Asthma Immunol; 2019 Aug; 18(4):427-440. PubMed ID: 31522451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic origin of T-cell epitopes within antibody variable regions: significance to monoclonal therapy and genesis of systemic autoimmune disease.
    Wysocki LJ; Zhang X; Smith DS; Snyder CM; Bonorino C
    Immunol Rev; 1998 Apr; 162():233-46. PubMed ID: 9602368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method.
    Roque-Navarro L; Mateo C; Lombardero J; Mustelier G; Fernández A; Sosa K; Morrison SL; Pérez R
    Hybrid Hybridomics; 2003 Aug; 22(4):245-57. PubMed ID: 14511570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for the development of therapeutic monoclonal antibodies.
    Swann PG; Tolnay M; Muthukkumar S; Shapiro MA; Rellahan BL; Clouse KA
    Curr Opin Immunol; 2008 Aug; 20(4):493-9. PubMed ID: 18586093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and engineering of deimmunized biotherapeutics.
    Griswold KE; Bailey-Kellogg C
    Curr Opin Struct Biol; 2016 Aug; 39():79-88. PubMed ID: 27322891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human monoclonal antibodies from transgenic mice.
    Lonberg N
    Handb Exp Pharmacol; 2008; 181(181):69-97. PubMed ID: 18071942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.